Neurosarcoidosis

Neurosarcoidosis is a complex disorder characterized by the presence of granulomas in the nervous system. With our expertise in neurosarcoidosis animal and in vitro models, preclinical research, and data analysis, we are at the forefront of developing innovative therapies for this debilitating disease.

Overview of Neurosarcoidosis

Neurosarcoidosis is a manifestation of sarcoidosis, a multisystem inflammatory disorder that primarily affects the lungs. However, in neurosarcoidosis, the disease involves the nervous system, leading to a wide range of neurological symptoms. These can include cranial nerve palsies, seizures, peripheral neuropathy, and cognitive impairment, among others. The exact pathogenesis of neurosarcoidosis is not fully understood, but it is believed to involve an immune-mediated response resulting in the formation of granulomas within the central and peripheral nervous system.

Schematic diagram of the pathogenesis model of Rasmussen encephalitis.Fig.1 Biopsy of a neurosarcoidosis-associated dural tumor shows noncaseating granulomas. (Tavee J. O., et al., 2014)

Therapy Discovery and Development for Neurosarcoidosis

TNF-alpha is a key cytokine involved in the pathogenesis of neurosarcoidosis, and inhibiting its activity can help suppress the inflammatory response. Infliximab, a chimeric monoclonal antibody targeting TNF-alpha, has demonstrated efficacy in inhibiting granuloma formation and inducing apoptosis in sarcoidosis. Other TNF antagonists, such as adalimumab, have also shown potential in the therapeutic of neurosarcoidosis. B cell-targeted therapy, such as rituximab, has been explored as a potential therapeutic for neurosarcoidosis, although its efficacy remains uncertain.

Below is a list of the therapeutic development services our company can provide. Please click on the links to learn more.

Our Services

Within our esteemed organization, we proudly spearhead the forefront of neurological diagnostics and therapy development for Neurosarcoidosis, with a steadfast commitment to delivering groundbreaking solutions for this complex disorder.

We understand the importance of reliable and representative models in preclinical research. Our team of experts specializes in developing animal models that mimic the pathophysiology of neurosarcoidosis, allowing for the evaluation of potential therapeutic interventions. Additionally, we employ in vitro models to investigate the mechanisms underlying neurosarcoidosis and test the efficacy of novel drug candidates.

Neurosarcoidosis animal model development services offered by our company encompass a range of specialized approaches. Induced animal models allow for the recapitulation of neurosarcoidosis pathology, while genetic modification models enable the unraveling of molecular mechanisms.

Customized Animal Models

We have access to a wide range of established cell lines that are relevant to neurosarcoidosis research, such as monocyte/macrophage cell lines and neuronal cell lines. These cell lines can be genetically modified or treated with specific stimuli to mimic neurosarcoidosis-related processes.

Cell-Based Models

Our company has the expertise to differentiate stem cells into brain organoids and induce neurosarcoidosis-like pathology within these models. To capture the systemic effects of the disease, we offer multi-organoid systems, where different organoids representing affected organs are interconnected.

Organoid Models

Through rigorous experimentation, we evaluate the pharmacokinetics, toxicology, and therapeutic potential of drug candidates. In addition to the extensive array of services and models mentioned earlier, our proficiency extends to tailoring personalized solutions and creating disease models that precisely cater to your specific requirements. We take pride in our ability to adapt and customize our offerings to meet your unique needs. If our comprehensive range of services has captured your attention, we sincerely welcome you to reach out to us without any hesitation.

References

  1. Tavee Jinny O., and Barney J. Stern. "Neurosarcoidosis." CONTINUUM: Lifelong Learning in Neurology 20.3 (2014): 545-559.
  2. Bradshaw Michael J., et al. "Neurosarcoidosis: pathophysiology, diagnosis, and treatment." Neurology: neuroimmunology & neuroinflammation 8.6 (2021): e1084.
For research use only. Not intended for any clinical use.